Compare Medpace Holdings Inc (MEDP) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Marqeta Inc — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Marqeta Inc trades at $17.48 (market cap $1.85B). The key difference: Medpace Holdings Inc is far larger — about 8.2× Marqeta Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | MQ | |
|---|---|---|
Market Cap | $15.08B | $1.85B |
Sector | Technology | Technology |
52-Week High | $620.59 | $27.32 |
52-Week Low | $308.88 | $15.04 |
Enterprise Value | $14.55B | $1.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Marqeta (MQ) trades at $17.45, down slightly by 0.23% today. The stock shows a bullish technical signal with strong moving average support, though RSI levels indicate mixed momentum. Fundamentally, the company reported revenue of $624.88M in 2025 (source: company filing 2025) but a net loss of $13.93M, with profitability metrics like net margin at 0.33% remaining thin. A recent 1-for-4 reverse stock split was effective July 1, 2026 (source: Business Wire 2026-06-29), aimed at boosting the share price amid restructuring efforts.
The outlook is cautiously optimistic with analyst consensus price target at $19.00 (source: MarketBeat 2026), implying potential upside, but high valuation ratios (P/E 436.88) and ongoing profitability challenges pose risks. Investor sentiment is mixed, balancing growth initiatives in Europe against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
